{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Checkpoint Inhibitor Therapy: Immune-related Adverse Event Management

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Explain the mechanism of action of immunotherapy using immune checkpoint inhibitors (ICIs) in the treatment of cancer.
  2. Identify immune-related adverse events (irAEs) associated with the use of ICIs for the treatment of cancer.
  3. Apply evidence-based management strategies for patients on ICIs who experience irAEs.

Learning Outcomes

By the conclusion of this activity, a majority of the participants will demonstrate knowledge of the potential adverse reactions associated with the use of immune checkpoint inhibitors for cancer treatment by achieving a passing score on the posttest.
Price: $21.95

Credits:

  • ANCC 2.0 CH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH
  • NM - BON 2.0 CH
  • SC - BON 2.0 CH
  • WV - BOERN 2.0 CH

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Test Code: N1124A
Published: Nov 2024
Expires: 12/4/2026
Sources: Nursing2024
Required Passing Score: 8/10 (80%)
Authors: Lori Davis, BSN, RN, OCN; Mary Beth Casselbury, BSN, RN, OCN; Sharon Wilson, RN, OCN